There is no denying the fact that cancer research has always been important, and that it continues to be important nowadays as well. Yet, some things have changed when it comes to that research. Basically, while previous studies have mostly been aimed at finding ways to kill cancer cells directly, modern research has now shifted towards understanding how to interfere with some support systems that tumors actually rely on. We are talking about metabolic pathways, growth signals, as well as the way the cells control their gene expression.
Shifting the focus towards those particular areas could help develop new drugs and new types of treatments that could help fight this disease. And, of course, there are various cancer support systems, so to speak, that scientists are interested in understanding better nowadays, with the PI3K and HDAC enzymes being among them. So, what scientists are doing nowadays is this – they are trying to basically combine two kinds of molecular blockers in one drug specifically. In this particular case, they are targeting a pathway that is usually overactive in cancer, that is, PI3K, as well as a pathway that actually alters how genes are regulated at the chromatin level, that is, HDAC.
This led to the development of a dual inhibitor drug that we are here to talk about today. In short, it is called Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor and it works to block the work of those two enzymes that we have mentioned above already. So, since you are here, there is no denying the fact that you are interested in understanding this drug better, as well as in realizing why it is that you should actually use it in your research.
Perhaps you’ve been thinking about getting it for your lab and including it in your research, but you are not entirely sure whether that is a good idea or not. Or what you would do with it precisely. So, what you want to do now is get a clearer picture on what it is, and why you may want to start using it in your research. And, if you are ready to learn about that, then you should undeniably keep on reading, because we will now answer those questions for you below. Without any further ado, thus, let us get started.
What Is Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor?
It goes without saying that we are going to begin with the most basic question here. That is, the question of what Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor actually is. After all, there is absolutely no point in talking in details about why you may want to use it in your research if you don’t really know what it is and how it works. So, without any further ado, let us start explaining things.
In the simplest words possible, Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor is actually a small molecule drug that inhibits two enzymes, that is, both PI3K and HDAC. It is designed to be administered orally, which makes things much more convenient for patients. And, so far, it has been studied in early clinical research for hematological malignancies, such as lymphoma, and multiple myeloma, as well as in some solid tumors as well.
What makes it stand out from some other types of inhibitors is precisely the fact that it has this dual inhibiting role. This means that scientists have the opportunity to study both the advantages and the challenges of dual inhibition. And, that can, without a doubt, be highly important in the process of developing new treatment options for cancer.
Read some more about it: https://haematologica.org/article/view/9686
Why Use It in Research?
Let us now move on to the next important question. You know what Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor is, and you now want to understand why it is that you may want to use it in your research. And, well, there are plenty of important reasons for that, so let us now check out some of them, hoping to give you a better idea about why it is that you may want to get this drug for your lab, and start your own studies and experiments.
- Testing the Dual Targeting Model
First things first, Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor allows you to research in details and test the dual targeting model. This means you can test the hypothesis that this kind of integrated targeting can actually outperform the single-target drugs. Furthermore, it helps you compare dual inhibition to the process of using two different inhibitors in combination.
- Exploring Combination Strategies
We all know that cancer therapy depends very much on combining various types of drugs and treatments. And, well, Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor, since it is a molecule that already merges two active mechanisms, can be quite useful in testing different combination strategies, and exploring what may work best for different types of cancer. So, you can test whether the dual inhibition actually enhances synergy.
- Researching Resistance and Adaptation
Resistance to treatment is one of the biggest problems that are faced while fighting cancer. When you get Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor for your lab, you can dive deeper into the explorations on what happens and how the cells reprogram and survive even when both the signaling and the epigenetic axis are challenged. In short, studying this can help you understand tumor plasticity.
- Studying Its Potential Beyond Cancer
Of course, you can also study the potential of this drug beyond oncology. It shows some promise in HIV latency reversal already. Furthermore, it also shows senolytic potential, killing damaged, aged and dysfunctional cells. You can, therefore, explore its implications further and check what it can be useful for beyond cancer.
How to Get It for Your Lab?
One final thing. If you’re wondering how to get Fimepinostat (CUDC-907) PI3K/HDAC Inhibitor for your lab, let me tell you right away that this shouldn’t be complicated, given that there are various chemical providers out there that can sell it to you. The idea is, naturally, for you to research different providers in more details, and ultimately choose those that are highly trustworthy and reliable, so that you can get a product that has a high level of purity.